• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2013-2017 年中国广东地区人感染甲型流感病毒(H7N9)的流行病学和临床特征。

Epidemiological and clinical characteristics of humans with avian influenza A (H7N9) infection in Guangdong, China, 2013-2017.

机构信息

Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, People's Republic of China.

Department of Medical statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, People's Republic of China.

出版信息

Int J Infect Dis. 2017 Dec;65:148-155. doi: 10.1016/j.ijid.2017.07.021. Epub 2017 Nov 8.

DOI:10.1016/j.ijid.2017.07.021
PMID:29128273
Abstract

OBJECTIVE

To describe the demographics and clinical characteristics of patients with A (H7N9) infection, to test the differences in the distribution of demographics and clinical characteristics by clinical severity, and to explore potential factors associated with clinical severity.

METHODS

This retrospective study was conducted to collect epidemiological and clinical information regarding the confirmed cases in Guangdong through field investigation and review of medical records.

RESULTS

Of the 256 cases, 100 (39.0%) patients died, and 168 (65.6%) patients were admitted to ICUs. The male-to-female ratio was approximately 2.0:1, and the median age was 56 years (range, 1 to 88). Among the 215 patients accepting oseltamivir treatment, the median time from the onset of illness to oseltamivir treatment was 5days (range, 0 to 16); 35 patients received zanamivir treatment after a median of 8days (range, 0 to 23). The univariable logistic regression models demonstrated that time from the onset of illness to oseltamivir treatment (OR=1.10, 95% CI=1.01-1.10) and zanamivir treatment (OR=1.05, 95% CI=1.02-1.07) were associated with the death of patients.

CONCLUSIONS

Preventive measures should focus on high-risk populations, such as the elderly and the groups with high frequency exposure to live poultry. Earlier oseltamivir and zanamivir treatment were recommended.

摘要

目的

描述 A(H7N9)感染患者的人口统计学和临床特征,检验临床严重程度分布的人口统计学和临床特征差异,并探讨与临床严重程度相关的潜在因素。

方法

本回顾性研究通过现场调查和病历回顾,收集了广东确诊病例的流行病学和临床信息。

结果

在 256 例病例中,100 例(39.0%)患者死亡,168 例(65.6%)患者入住 ICU。男女比例约为 2.0:1,中位年龄为 56 岁(范围 1-88 岁)。在接受奥司他韦治疗的 215 例患者中,从发病到接受奥司他韦治疗的中位时间为 5 天(范围 0-16 天);35 例患者在中位时间 8 天后(范围 0-23 天)接受了扎那米韦治疗。单变量逻辑回归模型表明,从发病到奥司他韦治疗(OR=1.10,95%CI=1.01-1.10)和扎那米韦治疗(OR=1.05,95%CI=1.02-1.07)的时间与患者死亡相关。

结论

预防措施应针对高危人群,如老年人和高频接触活禽的人群。建议尽早使用奥司他韦和扎那米韦治疗。

相似文献

1
Epidemiological and clinical characteristics of humans with avian influenza A (H7N9) infection in Guangdong, China, 2013-2017.2013-2017 年中国广东地区人感染甲型流感病毒(H7N9)的流行病学和临床特征。
Int J Infect Dis. 2017 Dec;65:148-155. doi: 10.1016/j.ijid.2017.07.021. Epub 2017 Nov 8.
2
Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013-17: an epidemiological study of laboratory-confirmed case series.2013 - 2017年中国大陆五次人感染H7N9禽流感病毒疫情的流行病学:实验室确诊病例系列的流行病学研究
Lancet Infect Dis. 2017 Aug;17(8):822-832. doi: 10.1016/S1473-3099(17)30323-7. Epub 2017 Jun 2.
3
Epidemiology of human influenza A(H7N9) infection in Hong Kong.香港人感染甲型流感病毒 H7N9 的流行病学。
J Microbiol Immunol Infect. 2017 Apr;50(2):183-188. doi: 10.1016/j.jmii.2015.06.004. Epub 2015 Jun 30.
4
Factors associated with clinical outcome in 25 patients with avian influenza A (H7N9) infection in Guangzhou, China.中国广州25例甲型H7N9禽流感感染患者临床结局的相关因素
BMC Infect Dis. 2016 Oct 3;16(1):534. doi: 10.1186/s12879-016-1840-4.
5
Clinical indices and mortality of hospitalized avian influenza A (H7N9) patients in Guangdong, China.中国广东住院人感染 H7N9 禽流感患者的临床指标与病死率。
Chin Med J (Engl). 2019 Feb 5;132(3):302-310. doi: 10.1097/CM9.0000000000000043.
6
Preliminary Epidemiology of Human Infections with Highly Pathogenic Avian Influenza A(H7N9) Virus, China, 2017.中国2017年人感染高致病性甲型禽流感(H7N9)病毒的初步流行病学研究
Emerg Infect Dis. 2017 Aug;23(8):1355-1359. doi: 10.3201/eid2308.170640. Epub 2017 Aug 15.
7
Epidemiological, clinical and viral characteristics of fatal cases of human avian influenza A (H7N9) virus in Zhejiang Province, China.中国浙江省人感染 H7N9 禽流感病毒死亡病例的流行病学、临床和病毒学特征。
J Infect. 2013 Dec;67(6):595-605. doi: 10.1016/j.jinf.2013.08.007. Epub 2013 Aug 16.
8
Fatal cases of human infection with avian influenza A (H7N9) virus in Shanghai, China in 2013.2013年中国上海人感染甲型H7N9禽流感病毒死亡病例
Biosci Trends. 2015 Feb;9(1):73-8. doi: 10.5582/bst.2014.01113.
9
[Epidemiology of human infection with avian influenza A(H7N9) virus in China, 2013-2017].《2013 - 2017年中国甲型H7N9禽流感病毒人间感染的流行病学》
Zhonghua Liu Xing Bing Xue Za Zhi. 2018 Jan 10;39(1):44-46. doi: 10.3760/cma.j.issn.0254-6450.2018.01.009.
10
Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection.与甲型流感病毒(H7N9)感染患者病毒持续排出相关的因素。
J Infect Dis. 2018 May 5;217(11):1708-1717. doi: 10.1093/infdis/jiy115.

引用本文的文献

1
Research progress on the effect of traditional Chinese medicine on the activation of PRRs-mediated NF-κB signaling pathway to inhibit influenza pneumonia.中药对激活模式识别受体介导的核因子κB信号通路抑制流感肺炎作用的研究进展
Front Pharmacol. 2023 Apr 7;14:1132388. doi: 10.3389/fphar.2023.1132388. eCollection 2023.
2
Immune Control of Avian Influenza Virus Infection and Its Vaccine Development.禽流感病毒感染的免疫控制及其疫苗研发
Vaccines (Basel). 2023 Mar 4;11(3):593. doi: 10.3390/vaccines11030593.
3
Antiviral effect of fufang yinhua jiedu (FFYH) granules against influenza A virus through regulating the inflammatory responses by TLR7/MyD88 signaling pathway.
复方银翘解毒颗粒通过 TLR7/MyD88 信号通路调节炎症反应对甲型流感病毒的抗病毒作用。
J Ethnopharmacol. 2021 Jul 15;275:114063. doi: 10.1016/j.jep.2021.114063. Epub 2021 Apr 1.
4
Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.含 MF59 佐剂的 H7N9 疫苗在 65 岁及以上健康成年人中不同剂量方案和抗原剂量的免疫原性和安全性。
Vaccine. 2021 Feb 22;39(8):1339-1348. doi: 10.1016/j.vaccine.2020.11.051. Epub 2021 Jan 21.
5
Clinical phase II and III studies of an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66 cell culture platform.采用 EB66 细胞培养平台生产的 AS03 佐剂 H5N1 流感疫苗的临床 II 期和 III 期研究。
Influenza Other Respir Viruses. 2020 Sep;14(5):551-563. doi: 10.1111/irv.12755. Epub 2020 Jun 24.
6
Specificity, kinetics and longevity of antibody responses to avian influenza A(H7N9) virus infection in humans.人类对禽流感 A(H7N9)病毒感染的抗体反应的特异性、动力学和持久性。
J Infect. 2020 Mar;80(3):310-319. doi: 10.1016/j.jinf.2019.11.024. Epub 2020 Jan 16.
7
Factors Associated With Fatality Due to Avian Influenza A(H7N9) Infection in China.与中国感染甲型 H7N9 禽流感导致死亡相关的因素。
Clin Infect Dis. 2020 Jun 24;71(1):128-132. doi: 10.1093/cid/ciz779.
8
Impacts of age and gender at the risk of underlying medical conditions and death in patients with avian influenza A (H7N9): a meta-analysis study.甲型H7N9禽流感患者潜在疾病风险和死亡风险中年龄及性别的影响:一项荟萃分析研究
Ther Clin Risk Manag. 2018 Sep 6;14:1615-1626. doi: 10.2147/TCRM.S173834. eCollection 2018.